Customer support

xie@china-sinoway.com
English
banner
Products
Home

Polypeptides

Pentadecapeptide BPC-157 137525-51-0

Pentadecapeptide BPC-157 137525-51-0

98% up by HPLC
  • Product Details

Product Information


Product name

Pentadecapeptide / BPC-157

CAS No.

137525-51-0

Sequence

gly-glu-pro-pro-pro-gly- lys-pro-ala-asp-asp-ala-gly-leu-val

Molecular Formula

C62H98 N16O22

Molecular Weight

1419.54

Quality Standard

98% up by HPLC

Appearance

White lyophilized powder


COA of Pentadecapeptide / BPC-157


ITEM

SPECIFICATIONS

RESULTS

Physical Control

Appearance

White Powder

Conforms

Odor

Characteristic

Conforms

Taste

Characteristic

Conforms

Purity

98%

Conforms

Loss on Drying

≤5.0%

Conforms

Ash

≤5.0%

Conforms

Particle size

95% pass 80 mesh

Conforms

Allergens

None

Conforms

Chemical Control

Heavy metals

NMT 10ppm

Conforms

Arsenic

NMT 2ppm

Conforms

Lead

NMT 2ppm

Conforms

Cadmium

NMT 2ppm

Conforms

Mercury

NMT 2ppm

Conforms

GMO Status

GMO Free

Conforms

Microbiological Control

Total Plate Count

10,000cfu/g Max

Conforms

Yeast & Mold

1,000cfu/g Max

Conforms

E.Coli

Negative

Negative

Salmonella

Negative

Negative

Conclusion: Conforms with standards.


Usage

Function of Pentadecapeptide / BPC-157


BPC 157 has a strong anti- inflammatory activity in both acute and chronic inflammation models. BPC 157 was shown to accelerate wound healing and to have a markedangiogenic effect.The preliminary results in clinical trials suggest that BPC 157 may become an important therapeutic tool for the treatment of inflammatory bowel disease.  In addition, it significantly facilitates the healing of bone fracture in rats. BPC 157 exhibits an osteogenic effect significantly improving the healing of segmental bone defect, and accelerates the healing of transected rat achilles tendon and transected rat quadriceps muscle.


Besides, BPC 157 induces f-actin formation in fibroblasts.The western blot analysis also showed that BPC 157 is able to increases the extent of phosphorylation of paxillin and fak proteins without affecting the amounts produced.

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

LIRAGLUTIDE
LIRAGLUTIDE 204656-20-2
Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage  2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: ·         Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. ·         Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). ·         Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. ·         Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.
matrixyl 3000
MATRIXYL 3000
Cosmetic Grade
nonapeptide-1
Nonapeptide-1
99% up by HPLC, Cosmetic Grade
Linaclotide
Linaclotide 851199-59-2
98% up, Medical Grade
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact